Resource Type

Journal Article 301

Conference Videos 2

Year

2023 31

2022 26

2021 22

2020 24

2019 11

2018 22

2017 17

2016 7

2015 25

2014 13

2013 8

2012 6

2011 10

2010 12

2009 7

2008 15

2007 17

2006 5

2005 2

2004 3

open ︾

Keywords

chemotherapy 3

different 3

non-linear 3

China 2

File system 2

Gut microbiota 2

Non-volatile memory (NVM) 2

development 2

management 2

non-alcoholic fatty liver disease 2

non-point source pollution control 2

non-small cell lung cancer 2

${\rm{NO}}_x $ removal 1

1

(DEM) 1

1) power model 1

2R-1C model 1

3D cell containers 1

3D formulation 1

open ︾

Search scope:

排序： Display mode:

Different sites of extranodal involvement may affect the survival of patients with relapsed or refractorynon-Hodgkin lymphoma after chimeric antigen receptor T cell therapy

Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 786-791 doi: 10.1007/s11684-020-0751-3

Abstract: complete and durable remissions after anti-CD19 chimeric antigen receptor T (CAR-T) cell immunotherapy for relapsedor refractory non-Hodgkin lymphoma (r/r NHL) have not been well characterized.

Keywords： anti-CD19 chimeric antigen receptor T cell     soft tissue     bone marrow     relapsed or refractory non-Hodgkin    

HTML PDF Collect

Primary spinal epidural non-Hodgkin’s lymphoma presented with spinal cord compression syndrome

Chunquan CAI MD, PhD, Qingjiang ZHANG BM, Changhong SHEN MD, PhD,

Frontiers of Medicine 2009, Volume 3, Issue 4,   Pages 499-502 doi: 10.1007/s11684-009-0075-9

Abstract: The spinal epidural space is an uncommon presenting site in primary non-Hodgkin’s lymphomas, especiallyA boy suffered spinal cord compression syndrome caused by primary spinal epidural non-Hodgkin’sHistological examination revealed a non-Hodgkin’s B-cell lymphoma.

Keywords： non-Hodgkin’     s lymphoma     primary     spinal cord compression syndrome     epidural space    

HTML PDF Collect

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 811-815 doi: 10.1007/s11684-020-0740-6

Abstract: immunomodulatory drugs, and inhibitors of B cell lymphoma-2 and Bruton’s tyrosine kinase have shown efficacy for relapsedor refractory (r/r) MCL but often have short-term responses.Chimeric antigen receptor (CAR) T-cell therapy has emerged as a novel treatment modality for r/r non-Hodgkin

Keywords： anti-CD19 chimeric antigen receptor T cells     mantle cell lymphoma     relapsed or refractory     long-term follow-up    

HTML PDF Collect

Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report

Xinping Zhou, Juying Wei, Yinjun Lou, Gaixiang Xu, Min Yang, Hui Liu, Liping Mao, Hongyan Tong, Jie Jin

Frontiers of Medicine 2017, Volume 11, Issue 2,   Pages 287-292 doi: 10.1007/s11684-017-0510-2

Abstract:

Castleman disease (CD) is an uncommon non-clonal lymphoproliferative disorder with unknown etiologyNo standard therapy is recommended for relapsed/refractory CD patients, thus requiring development ofOur cohort of three adult patients with multicentric CD (MCD) were treated with refractory to traditionalPartial remission was achieved in first plasma-cell CD patient, who relapsed seven months after autologous

Keywords： Castleman disease     lenalidomide    

HTML PDF Collect

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large

Frontiers of Medicine 2022, Volume 16, Issue 2,   Pages 285-294 doi: 10.1007/s11684-021-0843-8

Abstract: second-generation anti-CD19 CAR bearing 4-1BB costimulatory molecule, for the treatment of patients with refractoryTen heavily treated patients with refractory DLBCL were given CBM.CD19 CAR-T cell (C-CAR011) treatmentTherefore, C-CAR011 is a safe and effective therapeutic option for Chinese patients with refractory DLBCL

Keywords： CAR-T cell therapy     refractory diffuse large B-cell lymphoma     cytokine release syndrome     dose-limiting    

HTML PDF Collect

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 766-772 doi: 10.1007/s11684-021-0916-8

Abstract: the efficacy and safety of anlotinib as third- or further-line therapy in patients with short-term relapsedPatients with short-term relapsed SCLC (disease progression within 3 months after completing ≥ two linesFor patients with short-term relapsed SCLC, third- or further-line anlotinib treatment was associated

Keywords： anlotinib     chemotherapy     short-term relapsed     small-cell lung cancer    

HTML PDF Collect

thyroid-stimulating hormone during radiotherapy to prevent primary hypothyroidism in medulloblastoma/PNET and Hodgkin

Maura Massimino, Marta Podda, Lorenza Gandola, Emanuele Pignoli, Ettore Seregni, Carlo Morosi, Filippo Spreafico, Andrea Ferrari, Emilia Pecori, Monica Terenziani

Frontiers of Medicine 2021, Volume 15, Issue 1,   Pages 101-107 doi: 10.1007/s11684-020-0752-2

Abstract: therefore the protective effect of suppressing TSH with L-thyroxine during RT for medulloblastoma/PNET and Hodgkin

Keywords： iatrogenic primary hypothyroidism     late effects of radiotherapy     long-term follow-up     medulloblastoma     Hodgkin    

HTML PDF Collect

Boron neutron capture therapy of gliomas and refractory pituitary adenomas: current status and future

Dai Congxin,Yao Yong,Wang Renzhi

Strategic Study of CAE 2012, Volume 14, Issue 8,   Pages 96-99

Abstract: Moreover, BNCT may have a significant therapeutic effect on refractory pituitary adenomas which haveThis paper reviews the current status of BNCT for human liomas and the possibility to treat refractory

Keywords： boron neutron capture therapy     gliomas     refractory pituitary adenomas    

HTML PDF Collect

Second unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed

Frontiers of Medicine 2021, Volume 15, Issue 5,   Pages 728-739 doi: 10.1007/s11684-021-0833-x

Abstract: However, little is known about the efficacy of HSCT2 in patients with relapsed/refractory acute leukemiaTherefore, we retrospectively analyzed the efficacy of HSCT2 in 28 patients with relapsed/refractoryOur findings suggest that HSCT2 could be a salvage option for patients with relapsed AL post-Chemo+m-DLI

Keywords： second hematopoietic stem cell transplantation     acute leukemia     relapse     chemotherapy     modified donor lymphocyte infusion    

HTML PDF Collect

Degradation of refractory organics in concentrated leachate by the Fenton process: Central composite

Senem Yazici Guvenc, Gamze Varank

Frontiers of Environmental Science & Engineering 2021, Volume 15, Issue 1, doi: 10.1007/s11783-020-1294-1

Abstract: Abstract • 90% total COD, 95.3% inert COD and 97.2% UV254 were removed. • High R2 values (over 95%) for all responses were obtained with CCD. • Operational cost was calculated to be 0.238 €/g CODremoved for total COD removal. • Fenton oxidation was highly-efficient method for inert COD removal. • BOD5/COD ratio of leachate concentrate raised from 0.04 to 0.4. The primary aim of this study is inert COD removal from leachate nanofiltration concentrate because of its high concentration of resistant organic pollutants. Within this framework, this study focuses on the treatability of leachate nanofiltration concentrate through Fenton oxidation and optimization of process parameters to reach the maximum pollutant removal by using response surface methodology (RSM). Initial pH, Fe2+ concentration, H2O2/Fe2+ molar ratio and oxidation time are selected as the independent variables, whereas total COD, color, inert COD and UV254 removal are selected as the responses. According to the ANOVA results, the R2 values of all responses are found to be over 95%. Under the optimum conditions determined by the model (pH: 3.99, Fe2+: 150 mmol/L, H2O2/Fe2+: 3.27 and oxidation time: 84.8 min), the maximum COD removal efficiency is determined as 91.4% by the model. The color, inert COD and UV254 removal efficiencies are determined to be 99.9%, 97.2% and 99.5%, respectively, by the model, whereas the total COD, color, inert COD and UV254 removal efficiencies are found respectively to be 90%, 96.5%, 95.3% and 97.2%, experimentally under the optimum operating conditions. The Fenton process improves the biodegradability of the leachate NF concentrate, increasing the BOD5/COD ratio from the value of 0.04 to the value of 0.4. The operational cost of the process is calculated to be 0.238 €/g CODremoved. The results indicate that the Fenton oxidation process is an efficient and economical technology in improvement of the biological degradability of leachate nanofiltration concentrate and in removal of resistant organic pollutants.

Keywords： Concentrated leachate     Fenton oxidation     Central composite design     Biodegradability     Inert COD    

HTML PDF Collect

Reevaluation of the effect of Dianxianning on seizure rate of refractory epilepsy as additive treatment

Liyun He, Tiancai Wen, Shiyan Yan, Runjin Li, Zufa Liu, Hui Ren, Jinmin Liu, Fengshan Zhang, Jianzhong Wu, Jian Liu

Frontiers of Medicine 2011, Volume 5, Issue 2,   Pages 229-234 doi: 10.1007/s11684-011-0139-5

Abstract: We observed the effect of Dianxianning, which was used as additive treatment to treat 206 epilepsy patients, on the epilepsy seizure rate. Based on a multicenter, prospective, randomized, and controlled clinical trial design, we used the seizure rate of epilepsy as the main index. For the treatment group comprising 137 patients, we combined Dianxianning with chemical medicine, which is the basic treatment. For the control group with 69 patients, we added placebo. The results showed that 1) Effect on seizure rate: After a three-month treatment, the seizure rate of the treatment group decreased by 37.84% on average, whereas that of the control group decreased by 13.18% on average. Statistically comparing the two groups, there was a significant difference between these groups ( <0.05). 2) Effect on seizure frequency: As time passed, the frequency in each group gradually decreased. After a three-month treatment, there was a significant difference between the two groups ( <0.05). 3) Comparison between the before and after treatment of each group: There was a very significant difference between the two groups ( <0.0001). The results indicated that, as an additive treatment, Dianxianning has a good effect on controlling the epilepsy seizure rate and frequency management. It is more effective than using chemical medicine alone.

Keywords： Dianxianning     epilepsy seizure     evaluation    

HTML PDF Collect

Autologous peripheral hematopoietic stem-cell transplantation in a patient with refractory pemphigus

SUN Ledong, SUN Jing, ZENG Kang, MENG Fanyi, DIAO Youtao, XU Dan, HUANG Liang, ZHAO Jie, Liu Qifa

Frontiers of Medicine 2008, Volume 2, Issue 2,   Pages 191-194 doi: 10.1007/s11684-008-0036-8

Abstract: effectiveness of autologous peripheral hematopoietic stem-cell transplantation in the treatment of refractorysuggests that autologous peripheral hematopoietic stem cell transplantation may be a potential “cure” for refractory

Keywords： serological activity     leukapheresis     peripheral hematopoietic     cyclophosphamide     resistance    

HTML PDF Collect

Research on physical-chemical and biochemical combined technology in the treatment of refractory petrochemical

Tian Zhiyong,Tu Xiang,Song Yonghui,Xin Wang,Li Fayun

Strategic Study of CAE 2013, Volume 15, Issue 3,   Pages 80-87

Abstract: pilot-scale physical-chemical and biochemical combined technology tests were carried out for the treatment of refractoryIn addition, due to the lack of biodegradable organic carbon source and the refractory of acrylonitrile

Keywords： refractory     dry-spun     acrylic fiber wastewater     physical-chemical     biochemical     combined treatment    

HTML PDF Collect

A Nitride-Reinforced NbMoTaWHfN Refractory High-Entropy Alloy with Potential Ultra-High-Temperature Engineering Article

Yixing Wan,Yanhai Cheng,Yongxiong Chen,Zhibin Zhang,Yanan Liu,Haijun Gong,Baolong Shen,Xiubing Liang

Engineering 2023, Volume 30, Issue 11,   Pages 110-120 doi: 10.1016/j.eng.2023.06.008

Abstract:

Refractory high-entropy alloys (RHEAs) have promising applications as the new generation of high-temperaturethat exceeds the high temperature and strength of most known alloys, including high-entropy alloys, refractory

Keywords： Refractory high-entropy alloy     High temperature     Mechanical property     Microstructure     Strengthening mechanism    

HTML PDF Collect

Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamousnon-small-cell lung cancer: a retrospective analysis

Frontiers of Medicine 2022, Volume 16, Issue 4,   Pages 610-617 doi: 10.1007/s11684-021-0827-8

Abstract: anti-VEGF monoclonal antibody, has significantly improved the clinical outcomes of patients with advanced non-squamous

Keywords： bevacizumab     elderly patient     advanced non-small-cell lung cancer     overall survival     toxicity    

HTML PDF Collect

Title Author Date Type Operation

Different sites of extranodal involvement may affect the survival of patients with relapsed or refractorynon-Hodgkin lymphoma after chimeric antigen receptor T cell therapy

Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang

Journal Article

Primary spinal epidural non-Hodgkin’s lymphoma presented with spinal cord compression syndrome

Chunquan CAI MD, PhD, Qingjiang ZHANG BM, Changhong SHEN MD, PhD,

Journal Article

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Journal Article

Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report

Xinping Zhou, Juying Wei, Yinjun Lou, Gaixiang Xu, Min Yang, Hui Liu, Liping Mao, Hongyan Tong, Jie Jin

Journal Article

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large

Journal Article

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup

Journal Article

thyroid-stimulating hormone during radiotherapy to prevent primary hypothyroidism in medulloblastoma/PNET and Hodgkin

Maura Massimino, Marta Podda, Lorenza Gandola, Emanuele Pignoli, Ettore Seregni, Carlo Morosi, Filippo Spreafico, Andrea Ferrari, Emilia Pecori, Monica Terenziani

Journal Article

Boron neutron capture therapy of gliomas and refractory pituitary adenomas: current status and future

Dai Congxin,Yao Yong,Wang Renzhi

Journal Article

Second unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed

Journal Article

Degradation of refractory organics in concentrated leachate by the Fenton process: Central composite

Senem Yazici Guvenc, Gamze Varank

Journal Article

Reevaluation of the effect of Dianxianning on seizure rate of refractory epilepsy as additive treatment

Liyun He, Tiancai Wen, Shiyan Yan, Runjin Li, Zufa Liu, Hui Ren, Jinmin Liu, Fengshan Zhang, Jianzhong Wu, Jian Liu

Journal Article

Autologous peripheral hematopoietic stem-cell transplantation in a patient with refractory pemphigus

SUN Ledong, SUN Jing, ZENG Kang, MENG Fanyi, DIAO Youtao, XU Dan, HUANG Liang, ZHAO Jie, Liu Qifa

Journal Article

Research on physical-chemical and biochemical combined technology in the treatment of refractory petrochemical

Tian Zhiyong,Tu Xiang,Song Yonghui,Xin Wang,Li Fayun

Journal Article

A Nitride-Reinforced NbMoTaWHfN Refractory High-Entropy Alloy with Potential Ultra-High-Temperature Engineering

Yixing Wan,Yanhai Cheng,Yongxiong Chen,Zhibin Zhang,Yanan Liu,Haijun Gong,Baolong Shen,Xiubing Liang

Journal Article

Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamousnon-small-cell lung cancer: a retrospective analysis

Journal Article